Omeros Corporation OMER
Regular-session close
After hours · Nov 20, 4:01 PM ET
- YTD
- -23.11%
- 1 year
- +60.51%
5D -3.23 (-18.17%)
- Market cap
- 983.66M
- Revenue (ttm)
- 74.36M
- Profit margin
- 132.32%
- EPS (ttm)
- 0.83
- Shares out
- 74.46M
- P/E ratio
- 15.92
- Forward P/E
- 12.68
- YTD return
- -23.11%
- 1-year return
- +60.51%
- 50-day average
- 18.02
- Volume
- 2.02M
- Avg volume
- 1.37M
- Open
- 13.78
- Previous close
- 14.01
- Day's range
- 13.07 – 13.88
- 52-week range
- 8.23 – 21.05
- Beta
- 2.99
- Analysts
- Buy
- Price target
- 27.50 (+108.2%)
- Earnings date
- Mar 30, 2027
Key statistics
- 200-day average
- 13.82
- Enterprise value
- 1.18B
- PEG ratio
- 0.81
- Price / sales
- 14.03
- Free cash flow
- 192.61M
- Total cash
- 95.25M
- Total debt
- 193.80M
- Short % of float
- 17.91%
Fundamental scorecard
6 of 25 checks passed on OMER’s reported financials
6of 25 checks passed
- Value 1 of 5
- Growth 2 of 5
- Profitability 1 of 5
- Financial health 2 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: buy
- Target (low)
- 22.00
- Target (mean)
- 27.50
- Target (high)
- 33.00
- Strong buy0
- Buy2
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 30, 2027
Expected Mar 30, 2027. Consensus EPS estimate 0.085.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 30, 2027 | Mar 30, 2027 | -0.09 | — | — | — |
| Nov 16, 2026 | Sep 30, 2026 | 0.02 | 0.06 | +0.04 | +200.00% |
| Aug 13, 2026 | Jun 30, 2026 | -0.2683 | 0.15 | +0.42 | +155.91% |
| May 13, 2026 | Mar 31, 2026 | -0.40 | -0.24 | +0.16 | +40.00% |
| Mar 31, 2026 | Dec 31, 2025 | -0.55 | 3.14 | +3.69 | +670.91% |
| Nov 13, 2025 | Sep 30, 2025 | -0.58 | -0.47 | +0.11 | +18.97% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 17, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 14, 2026 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Sep 22, 2026 | Cantor Fitzgerald | up | Neutral | Overweight |
| Jun 26, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jun 10, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| May 14, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
About Omeros Corporation
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- omeros.com
News
Omeros: Yartemlea Commercial Momentum Supports Upgrade Despite Q3 Deceleration (Rating Upgrade)
Why Is Omeros Stock Trading Lower Tuesday? HC Wainwright & Co. Reiterates Buy on Omeros, Maintains $33 Price Target
Red Cat Downbeat Q3 Results, Joins Omeros, Deutsche Bank And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
Omeros Q3 Earnings Call Highlights
Omeros Corporation (OMER) Q3 2026 Earnings Call Transcript
Omeros (OMER) Surpasses Q3 Earnings and Revenue Estimates
12 Health Care Stocks Moving In Monday's After-Market Session Omeros Q3 Adj. EPS $0.06 Beats $0.03 Estimate, Sales $35.934M Miss $37.267M Estimate
Omeros Corporation Reports Third Quarter 2026 Financial Results
Your note
Sign in to keep a note on OMER — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BORGES DAVID J. | Officer | Sale | Sep 22, 2026 | 0 |
| CABLE THOMAS J | Director | Sale | Aug 19, 2026 | 35,067 |
| CANCELMO PETER B. | General Counsel | Sale | Aug 30, 2026 | 200 |
| DEMOPULOS GREGORY A. M.D. | Chief Executive Officer | Conversion of Exercise of derivative security | Feb 17, 2026 | 2,193,250 |
| HANISH ARNOLD C | Director | Sale | Aug 26, 2026 | 12,400 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.35% | 6,046,101 | 84.71M | Sep 29, 2026 |
| Ingalls & Snyder LLC | 4.28% | 3,095,323 | 43.37M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 4.22% | 3,058,096 | 42.84M | Sep 29, 2026 |
| UBS Group AG | 4.10% | 2,970,107 | 41.61M | Sep 29, 2026 |
| State Street Corporation | 3.10% | 2,240,906 | 31.40M | Sep 29, 2026 |
| Geode Capital Management, LLC | 2.62% | 1,895,961 | 26.56M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.00% | 2,172,336 | 30.43M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.58% | 1,867,153 | 26.16M | Sep 29, 2026 |
| Invesco Exchange-Traded Fund Trust-Invesco Biotechnology & Genome ETF | 1.28% | 929,585 | 13.02M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.15% | 831,218 | 11.65M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.09% | 789,898 | 11.07M | Aug 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Pharmaceuticals ETF | 0.74% | 533,750 | 7.48M | Sep 29, 2026 |
